Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Evonik And Akzo Eye End To Mercury Cl2
by Michael McCoy
July 28, 2014
| A version of this story appeared in
Volume 92, Issue 30
Evonik Industries and AkzoNobel are in talks about building a membrane-based chlor-alkali facility at Akzo’s site in Ibbenbüren, Germany. To produce chlorine and potassium hydroxide, the plant will replace similar mercury-cell-based operations at the site. The partners expect the facility to open in the third quarter of 2017 in advance of a new law that requires the end of mercury-based production by 2018. Akzo will market chlorine and hydrogen. Evonik will market potassium hydroxide, converting some to potassium carbonate at its plant in Lülsdorf, Germany.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter